We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Proteins in Head and Neck Cancer Cells

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00896948
First Posted: May 12, 2009
Last Update Posted: March 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Vanderbilt University Medical Center
  Purpose

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.


Condition Intervention
Head and Neck Cancer Genetic: Southern blotting Genetic: TdT-mediated dUTP nick end labeling assay Genetic: gene expression analysis Genetic: protein expression analysis Other: flow cytometry Other: fluorescent antibody technique Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique

Study Type: Observational
Official Title: Novel Protein Regulator of Tumor Suppressor ARF & NF-κB

Resource links provided by NLM:


Further study details as provided by Vanderbilt University Medical Center:

Primary Outcome Measures:
  • Function and mechanism of LZAP in regulating ARF
  • Mechanism and biological consequences of LZAP inhibition of NF-κB
  • Determination of LZAP tumor suppressor activity

Study Start Date: May 2005
Detailed Description:

OBJECTIVES:

  • Define the function and mechanism of LZAP in regulating ARF.
  • Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
  • Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.

OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Head and neck cancer tumor cell line

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00896948


Locations
United States, Tennessee
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States, 37064
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States, 37064
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838
Sponsors and Collaborators
Vanderbilt University Medical Center
National Cancer Institute (NCI)
Investigators
Study Chair: Wendell G. Yarbrough, MD, FACS Vanderbilt-Ingram Cancer Center
  More Information

Responsible Party: Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT00896948     History of Changes
Other Study ID Numbers: CDR0000558974
P30CA068485 ( U.S. NIH Grant/Contract )
VU-VICC-HN-0529
VU-VICC-IRB-050259
First Submitted: May 9, 2009
First Posted: May 12, 2009
Last Update Posted: March 14, 2017
Last Verified: March 2017

Keywords provided by Vanderbilt University Medical Center:
head and neck cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Antibodies
Immunologic Factors
Physiological Effects of Drugs